Diffuse Large B-Cell Lymphoma: Drugs Under Investigation

Many individual and combination treatments and therapeutic strategies are presently being studied in clinical trials for treating both newly diagnosed and relapsed/refractory DLBCL, including:

Alisertib (MLN3237) Lenalidomide (Revlimid)
Brentuximab vedotin (Adcetris) Nivolumab (Opdivo)
  Panobinostat (Farydak)
Everolimus (Afinitor) Vorinostat (Zolinza)


These clinical trials are investigating the use of these agents at various treatment stages (first-line, maintenance, etc.) and in specific patient populations, including newly diagnosed patients, patients with relapsed or refractory disease, the elderly, and those with specific molecular subtypes. The trials investigating these drugs are also in various phases of development (i.e., research in some trials investigating one agent has progressed further than research in other trials investigating another drug).

It is critical to remember that today’s scientific research is continuously evolving and that treatment options may change as new treatments are discovered and current treatments demonstrate effectiveness against further subtypes and other diseases. Therefore, it is important that patients check with their physician or with LRF for any treatment updates that may have recently emerged.


Next Section:  Clinical Trials